快要 飞的 《药股》 讨论区

葉芬

分享：


http://www.fool.com/investing/sm ... e-next-4-years.aspx


The Best Stocks for the Next 4 Years

By Adam J. Wiederman
September 28, 2009 | Comments (8)

It sure is starting to look like this bear market is over, isn't it?

We can't be sure just yet, though investors in CEL-SCI (AMEX: CVM), YRC Worldwide (Nasdaq: YRCW), Quantum Fuel Systems Technologies Worldwide (Nasdaq: QTWW), ATP Oil & Gas (Nasdaq: ATPG) are likely convinced. Each of those stocks is up more than 50% ... over the past month alone.

Some analysts, like PIMCO's Mohamed El-Erian, believe that the rally is over, and that "valuations are ahead of fundamentals."

。。。。。。。

葉芬

http://daytradingstockblog.blogs ... october-5-2009.html


Spectrum Pharmaceuticals, Inc. (SPPI) - Keep an eye on SPPI as the FDA will give their decision on Fusilev ( colon cancer drug ) on Oct. 8th.


Novavax, Inc. (NVAX) - Looking to buy NVAX for a trade when the stock closed back above the 10 day moving average ( currently $4.15 ).

葉芬

分享：

CVM


http://blog.wenxuecity.com/bloga ... 09&postID=40444


CVM potential is the sky limit. current vaccine is not safe and cvm seems the only back up currently in addition to its only treatment available for the Swine flu patient.. and not even mention its cancer drug.. I believe the price will increase before 10/7.

September 29, 2009 10:58:27 AM EDT


Government scrambling to search for answers to swine flu pandemic
Pablo Y Romanus, M.D.September 28, 2009
The fact that schools, universities and other places where large groups gather are starting to report a record numbers of absence rates tells us that the H1N1 pandemic has officially arrived here, early.

\"This would be comparable to what we would see in a moderate flu season in January or February,\" says Mark Springer, the Spokane Regional Health District\'s epidemiologist. \"This is just a snapshot in time. We would anticipate increases.\"

According to a special report in Friday\'s Time Magazine, across the country, the pattern is much the same. This year\'s novel flu virus is hitting much sooner than normal, long before cold weather forces people inside, where viruses like to fester, and weeks before the official start of flu season on Oct. 4. The virus has been gobbling geographic terrain in recent weeks, with 26 states reporting widespread flu illness on Sept. 19, up from 21 states a week earlier and just four states at the beginning of August. On the CDC\'s website, one can find a flu situation update that provides several research indicators that point out the same thing in alarming fashion......

文章太長，沒有Post完全部，自己Click Link 查看下。

葉芬

CEL-SCI Corp. (CVM) Support & Resistance Levels - 10/5/09

Resistance Levels - $1.74, $1.77, $1.83, $2.10

Support Levels - $1.60, $1.52, $1.34, $1.10





CEL-SCI Corp. (CVM) continues to hold the major support level of $1.60 ever since making the low of $1.52. If CVM falls below $1.60, I'd be a seller of the stock. Right now, there is major resistance at the 10 day moving average ( $1.74 ) and $1.77. As soon as CVM closes over $1.80, I will get back into the stock in a big way with a tight stop at the 10 day moving average. If positive news comes out and CVM breaks the $2.10 high, look out above! All serious day traders should have CVM on their watch lists.

CHLaw

YMZ09.CBT

Mini Dow Jones Indus.-$5 Dec 09

9,472.00  2:33am ET

37.00 (0.39%)

葉芬

Cel-Sci May Be in for a Bumpy Ride
by: VFC's Stock House October 05, 2009 | about: CVM   


It looks like the writing staff at BioMedReports.com, most notably M. E. Garza, must be getting under Adam Feuerstein's skin because he's decided to enact a personal vendetta with the website. The thing is, it makes Adam and his puppetmasters at the The Street.com looks pretty bad when other sites post facts about a company and its stock, and then form opinions based on those facts. Since BioMedReports was doing just that, Adam decided to bash that website along with a bash on Cel-Sci (CVM).

It's my opinion that the Adam bash parade is starting to lose steam, in my opinion, in the same way that the 'cry wolf' ended up losing steam for 'The Boy Who Cried Wolf'. Any positive news from CVM this week will negate any downside influence that Adam F. had on the stock.

The only ones that follow the Street.com any more are the big boys that count on them to bash or pump whenever they need a puppet to do their bidding - which does not include looking out for the little guy. When Feuerstein tells a story, he only tells you part of the story.

Regardless of the Adam F. controversy, there's quite a bit of news pending during the fourth quarter - including Multikine news, the opening of the Baltimore facility and LEAPS - that could influence the price of this stock. It could get bumpy this week - if there is no news released I wouldn't be surprised to see the stock dip down to below the $1.50 level one more time.

Disclosure: VFC is long CVM.

葉芬

http://seekingalpha.com/article/ ... -eye-on?source=feed



5 Biotech Stocks to Keep an Eye On
by: M. E. Garza October 05, 2009 | about: AVII / CVM / HGSI / INO / ONCY   


Oncolytics Biotech, Inc. (NASDAQ:ONCY) makes our list of stocks to watch after reaching an agreement with the U.S. Food and Drug Administration under the special protocol assessment process for the design of a Phase 3 trial examining REOLYSIN in head and neck cancers.

On Friday, Oncolytics said it's the first company to reach an agreement with the FDA on a Phase 3 trial design for an IV-administered oncolytic virus under the SPA process. The SPA is an agreement between Oncolytics and the FDA that the design and planned analyses of the Phase 3 study is adequately designed to provide the necessary data. The stock traded above it's 52-week high on Friday, but shares ticked down a bit after hours. As news spreads about this key development, interest in the company may rise as well since a license application submission for REOLYSIN would become a major development for the Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.

Insiders at Cel-Sci Corporation (AMEXVM) had been buying up shares at open market prices just days before a vastly under researched story hit the news wires on Friday. Rumors about the latest report filings with the SEC had begun to spread and had prices for shares significantly rising above market close last Thursday after hours, but enthusiasm for the stock was dampened when the hit piece from the Street.Com took aim at them.

If you watch patterns, you've seen the same type of "bullish" insider buying activity take place on countless other occasions, but perhaps the most recent example comes from Human Genome Sciences (NASDAQ:HGSI) just days before news about BENLYSTA made shares jump significantly.

Specific details about a number of upcoming catalysts have yet to be disclosed by the company, but readers of this space know that the Cel-Sci has several pending news items due, including the unveiling of their new state-of-the-art cold fill laboratory, any number of announcements regarding their newly (FDA) fast-tracked H1N1 flu treatment human studies as well as official news about the launch of Phase III studies for Multikine.

Multikine is the company's multi-targeted, cancer immunotherapy which performed well in Phase II, but had been sidelined while said laboratory was being built to accommodate the production of the sensitive and complex biologic drug candidate platform.

Those looking for "tells," certainly point to news about the new laboratory as one such positive indicator. Would a publicly traded company spend a rumored $20-$25 million on a new lab to produce a their cancer vaccine if they didn't have enough scientific proof that the drug would perform well in Phase III? The United States Food and Drug Administration (FDA) certainly concurred with the initiation of a global Phase III clinical trial in head and neck cancer patients using Multikine back in January 2007, so this development would qualify as long awaited good news for the stock.

Upcoming news might also be related to the company's inclusion in the latest Vaccine Identification Standards Initiative. The office of the Chief Science Officer for the CDC has just added Cel-Sci to his comprehensive list of vaccine and biologics manufacturers and distributors. The company did not appear on documents previously released by the Centers for Disease Control and Prevention.

Another stock to watch is AVI BioPharma, Inc.(NASDAQ:AVII). The Wall Street Journal (see their video commentary here) and others seem to have taken an interest, as the company's drug for the worst form of muscular dystrophy moves toward FDA approval. The stock could also surge if the company becomes an acquisition target- as rumored.

Dr. Eric Hoffman, a leading Duchenne researcher at the Children's National Medical Center in Washington, said that he is very convinced this drug will work. Meanwhile, Prosensa, a Dutch company developed their own muscular dystrophy drug that is considered a promising treatment, alongside AVII's.

Marketing for such a drug is still some time away (perhaps 2012-2013) but it could bring over $1 billion in sales for the company and that makes it an attractive stock for longer term speculators.

AVI Biopharma, Inc. (AVI) has also developed the treatments for a coronary artery blockage, and for Ebola and Marburg. These drugs are also in early-stage trials. Barron's has published that it must be noted that AVI Biopharma, Inc. (AVII) has disappointed in the past, when its drug for hepatitis failed to pass the trials. The biopharmaceutical company specializes in the discovery and development of ribonucleic acid (RNA)-based drugs targeting a range of diseases.

Finally, Inovio Biomedical Corporation (NYSE Amex: INO) announced interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial and that could make it a big gainer. According to the company, the vaccine was found to be generally safe and well tolerated, and achieved significant cellular and humoral immune responses at the lowest dose administered. A news report about those newly reported findings can be read at BioMedReports.

Disclosure: Long CVM

葉芬

Inovio Biomedical Corporation (INO.A) (American Stock Exchange)



Inovio Biomedical Corp. Demonstrates Protective Immune Responses Against Novel H1N1 (2009) Influenza Virus in Ferret Model
5:30am EDT

Inovio Biomedical Corp. announced that a combination of its synthetic consensus (SynConTM) H1N1 influenza vaccine candidates achieved protective antibody responses against the novel pandemic influenza A/H1N1 (2009) in 100% of tested ferrets. The ferret model is widely considered to be the most representative of human influenza; achieving in ferrets a level of antibody titers commonly associated with protection in humans is a critical milestone in influenza vaccine development. Following promising results in mice and pigs with SynCon H1N1 DNA vaccine candidates, as referenced in previous news releases, in this study Inovio scientists immunized ferrets with a formulation of H1N1 DNA vaccine candidates. They then tested the ferrets` serum for hemagglutination inhibition (HI) responses against one of the 2009 pandemic H1N1 strains, A/H1N1/Mexico/InDRE4487/2009. HI measurements from the blood of vaccinated animals are used to assess the generation of protective antibody responses. Generating an antibody titer of 1:20 is generally regarded as a positive vaccine response, with a titer of 1:40 or higher in the blood of vaccinated subjects generally associated with protection against influenza in humans. In this experiment, a single vaccination showed induction of positive immune responses in 78% (7 of 9) of ferrets, with a mean HI titer of 1:42. After two booster shots, 100% of immunized ferrets had HI titers greater than 1:40, with the mean titer rising to 1:390.

Inovio Biomedical Corp. Therapeutic Cervical Cancer Vaccine Demonstrates Safety And Immunogenicity In Clinical Trial
2:00am EDT

Inovio Biomedical Corp. announced interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation. The vaccine was found to be generally safe and well tolerated, and achieved significant cellular and humoral immune responses at the lowest dose administered. This phase I clinical trial was designed to test the safety and immunogenicity of VGX-3100 in women with a previous history of cervical intraepithelial neoplasia (CIN) 2/3, a precursor lesion prior to the development of cancer. This dose escalation study is enrolling patients in three cohorts of six subjects each with DNA vaccine doses at 0.6 mg (0.3 mg each of two DNA plasmids), 2.0 mg, and 6.0 mg. The immunization regimen consists of each subject receiving three immunizations at the indicated dose. The vaccine is delivered using Inovio Biomedical Corp.'s CELLECTRA intramuscular electroporation delivery device. Inovio Biomedical Corp. has completed immunizations of the lowest dose cohort. The interim safety analysis indicated that all six subjects tolerated the vaccine administration and electroporation procedure well over each of the three vaccinations. In general, reported adverse events and injection site reactions were mild to moderate and required no treatment.

m.i.k.e

之前说的 DEPO.........飞了 !

DEPO
4.41
0.00 (0.00%)
Pre-market: 6.10 +1.69 (38.32%) <<<<<< (没买到.)

有没有人买进??

DepoMed, Inc. Announces Positive Top-Line Results From Phase 3 Clinical Trial Of DM-1796 In Postherpetic Neuralgia
7:00am EDT
DepoMed, Inc. announced top-line results from a Phase 3 clinical trial demonstrating DM-1796 (also referred to as gabapentin ER) achieved a statistically significant reduction in pain associated with postherpetic neuralgia (PHN) versus placebo using the baseline observation carried forward (BOCF) method required by FDA. The primary endpoint measured pain scores from baseline to the end of a ten-week treatment period using the numerical Likert pain scale. DM-1796 is an investigational extended release, once-daily tablet formulation of gabapentin for the treatment of PHN. Depomed has licensed DM-1796 to Solvay Pharmaceuticals, Inc. in the United States, Canada and Mexico for the treatment of pain.

葉芬

原帖由 m.i.k.e 于 5-10-2009 08:31 PM 发表
之前说的 DEPO.........飞了 !

DEPO
4.41
0.00 (0.00%)
Pre-market: 6.10 +1.69 (38.32%)  

有看沒買。
沒$$進了。。

我還以為你自己有買。。

m.i.k.e

原帖由 葉芬 于 5-10-2009 08:35 PM 发表



有看沒買。
沒$$進了。。

我還以為你自己有買。。

我没时间研究.

叫你得空研究一下,你连个反应都没......
只顾着 pm 开户口的资料给新人.

葉芬

原帖由 m.i.k.e 于 5-10-2009 08:42 PM 发表

我没时间研究.

叫你得空研究一下,你连个反应都没......
只顾着 pm 开户口的资料给新人.

哎呀 別這樣說。。
我顧著看CVM / HLCS。。。

miku

姐姐，为什么ino，avii起，cvm跌呢？谢谢

雨若情

我就是那个新人咯。
之前只会在澳洲混。
芬姐介绍我移民美国。
第一次战绩：
星期四15.50进了lvs
今晚17.00我就丢咯
然后去cvm排队

[ 本帖最后由 雨若情 于 6-10-2009 01:51 AM 编辑 ]

wobushi

原帖由 m.i.k.e 于 30-9-2009 05:06 PM 发表


得空的话也研究下 CXM.....研究报告就要公布了....是飞?是跌? 自己看着办.
Depo 也一样.

你说得很准呀，每次被你点名的都起

10/5/2009  Market Closed

NASDAQ Last Sale 1.59     0.29    22.31%

钻石与水

看来LVS真得帮到不少人。。。
LVS应该回到19左右吧，无论如何我会持票。。
现在我把重心都放在THC和PLD。。。有人买这两间公司吗？

葉芬

原帖由 miku 于 6-10-2009 12:50 AM 发表
姐姐，为什么ino，avii起，cvm跌呢？谢谢

CVM 的 Letter to Shareholder 的新聞不夠Solid來Support她的股價。

http://www.prnewswire.com/news-releases/cel-sci-corporation-releases-letter-to-shareholders-63539002.html

現在我在等著 PR on the facility 的新聞。。。這新聞一出，估計價錢會過2元。



XXXXXXXXXXXXXXXXXXXXXXXXXXX



CEL-SCI Corp. (CVM)- The $1.60 support level was broken on Monday. This is very bearishbut not the end of the world. As soon as CVM starts tradingsuccessfully back over $1.60, I will jump back into the stock.

http://daytradingstockblog.blogspot.com/2009/10/stocks-to-buy-10609-october-6-2009.html

[ 本帖最后由 葉芬 于 6-10-2009 12:04 PM 编辑 ]

葉芬

Miku，你的VG走勢不錯。

Vonage Holdings Corporation (VG) - VG popped Monday on smart phone app news. A close above $1.61 would be very bullish and I think the stock could eventually test $2. VG is now trading above the 10 day moving average.

葉芬

Discovery Laboratories Inc. (DSCO) - DSCO hit resistance of $1.20 on Monday but then sold off. I am watching for a break above $1.21 going forward.

葉芬

YMZ09.CBT        Mini Dow Jones Indus.-$5 Dec 09        9,568.00  4:05am ET        Up 22.00 (0.23%)